Kyverna Therapeutics Inc stock is traded at $4.61, with a volume of 1,432,499. It is down -10.66% in the last 24 hours and down -25.16% over the past month. Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Previous Close:
$5.16
Open:
$5.11
24h Volume:
1,432,499
Relative Volume:
1.60
Market Cap:
$285.10M
Revenue:
$282.00K
Net Income/Loss:
-$156.40M
P/E Ratio:
-
EPS:
-$3.28
Net Cash Flow:
-$151.53M
1W Performance:
-18.69%
1M Performance:
-25.16%
6M Performance:
-51.32%
1Y Performance:
-34.98%
1-Day Range:
$0.00$0.00
1-Week Range:
$4.50$5.84
52-Week Range:
$4.50$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(510) 626-8331Address
5980 HORTON STREET, EMERYVILLE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS